Cure Leukaemia founder, Prof Charlie Craddock said: "Leukaemia is the most common form of cancer in children, and almost half of those diagnosed with the disease are under the age of five.
s "Huge progress in treatment has been made over the past 50 years and today more than 80 per cent of children diagnosed with the commonest type of childhood leukaemia can be cured.
Dr Willmore said: "Some patients with chronic lymphocytic leukaemia become very ill and the cancer becomes resistant to the chemotherapy, so we need new and more effective treatments to overcome this.
Drugs that are used to treat this type of leukaemia work by damaging the DNA of the leukaemia cells in the blood.
Cells in chronic leukaemia
are slightly abnormal and do not function as well as they should do.
Acute Myeloid Leukaemia Phase 3 Clinical Trial Pipeline Insights
Acute Myeloid Leukaemia Phase 2 Clinical Trial Pipeline Insights
John Seymour MBBS FRACP, Chairman of the Australasian Leukaemia
and Lymphoma Clinical Trials Group said: "The clinical data presented at recent international conferences on the use of Evoltra(R) in elderly patients with AML appear very promising, with encouraging efficacy and good tolerability.
This approach is more likely to address the heterogeneity of acute leukaemia and will contribute to the increasing trend of risk-stratified treatment approaches.
Reflecting a greater understanding of disease biology, the enthusiastic pursuit of Flt-3 inhibition in the development of novel acute myeloid leukaemia treatment has resulted in already crowded pipeline, with four products challenging for first-to-market status: Cephalons CEP-701, Novartis PKC-412, Millenniums MLN518 and Pfizers SU11248.
Clofarabine was submitted to the FDA for approval in March 2004 and to the EMEA for approval in July 2004, in each case, for the treatment of refractory or relapsed acute leukaemia
Nasdaq:ILXO), submitted the first part of the "rolling" NDA for clofarabine in October 2003, after the drug was granted fast-track designation in refractory and relapsed pediatric leukaemia.
If approved by the FDA, clofarabine would be the first drug to be labeled for pediatric leukaemia exclusively in more than a decade.
Nasdaq:ILXO), submitted the first part of the "rolling" NDA in October 2003, after clofarabine was granted fast-track designation in refractory and relapsed paediatric leukaemia.
The filing was based on data from two pivotal Phase II trials in acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML) which will be presented at the 40th American Society of Clinical Oncology annual meeting in June.